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Supplementary Figure 1.  Sensitivity analyses showing the cost effectiveness plane corresponding to 
Figure  2 of the main manuscript after making single changes to the model and assumptions as indicated.  These 
figures correspond to Table 3 of the main manuscript. 
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Modelling Methods 
1. Summary of calibration to Zimbabwe 
The HIV Synthesis Transmission model is an individual-based stochastic model of heterosexual transmission, 
progression and treatment of HIV infection within a southern African context (Phillips et al 2011, Cambiano et al 
2013, Cambiano et al 2014).  Details of the model are given in subsequent sections below.  For this project we 
calibrated the model to data on HIV prevalence, testing patterns and ART use from Zimbabwe.  Figure S1 shows 
the calibration to past data on HIV prevalence.  Table S1 shows the modelled outputs for the year 2014, 
together with observed data for some aspects.  
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2.  Demographic model  
 
General population death rates and determination of age in 1989 
The model runs to from 1989 (the start of the epidemic) to 2039 (although in our results we concentrate on the 
20 year period to 2035), with variables updated in 3 month periods.  Each run of the simulation program creates 
100,000 simulated people who will be age 15 or above at some point between 1989 and 2035, of whom 
approximately 50,000 are alive and age over 15 at any one point in time.  In order to scale up from the simulated 
population to the actual population in Zimbabwe we use a scale factor of 228. 
 
In the absence of data on death rates considerd reliable for Zimbabwe, age specific death rates for uninfected 
people are based on death rates in South Africa in 1997 (Table S2) – before the significant impact of HIV-related 
deaths.  These rates were modified by a factor 2-fold in order to mimic the population pyramid in Zimbabwe 
(Table S3).  
 
Table S2.  Age specific death rates (per year) 
 
Age group Annual death rate  
-------------------------------------------- 
Males 
  
15-19   0.00400 
20-24   0.00640 
25-29   0.01160 
30-34   0.01500 
35-39   0.01600 
40-44   0.02000 
45-49   0.02400 
50-54   0.03800 
55-59   0.05000 
60-64   0.07000 
65-69   0.09000 
70-74   0.11000 
75-79   0.13000 
80-84   0.20000 
>85   0.80000 
 
Females 
 
15-19  0.00300 
20-24  0.00560 
25-29  0.00800 
30-34  0.00800 
35-39  0.00840 
40-44  0.01100 
45-49  0.01500 
50-54  0.02200 
55-59  0.03000 
60-64  0.04200 
65-69  0.06000 
70-74  0.07600 
75-79  0.10000 
80-84  0.14000 
>85   0.30000 
-------------------------------------------- 
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Table S3.  Observed and modelled populationsize by age in 2014. 
 
  Male      Female 
   
  Observed  Model   Observed  Model 
--------------------------------------------------------------------------------------------------------------------------------------------------
15-24 years:   1.55m   1.56m     1.53m      1.54m  
25-54 years:   2.48m   2.25m   2.27m     2.66m 
55-64 years:   1.85m   0.22m    3.24m      0.41m  
65 years and over:  0.19m   0.13m    0.30m     0.37m 
-------------------------------------------------------------------------------------------------------------------------------------------------- 
 
Observed data from CIA world factbook (2014)   https://www.cia.gov/library/publications/the-world-
factbook/geos/zi.html 
 
 
 
The initial age distribution for both males and females is determined on the basis of the distribution in Table S4. 
 
Table S4.  Distribution of ages of simulated individuals in 1989 
 
  Probability 
Age group of being in age 
  group in 1989* 
------------------------------------------- 
-35-14   0.720 
 15-24   0.091 
 25-34    0.075 
 35-44  0.062 
 45-54  0.033 
 55-64  0.021 
-------------------------------------------- 
 
This distribution is chosen such that in the absence of HIV, given the death rates above, the population size 
increases over time.  Thus around 72% of simulated people have an age below 15 in 1989.  The only variable that 
is modelled and updated up to reaching the age of 15 (when becoming potentially sexually active) is age itself. 
The “youngest” person in 1989 is age -35 (i.e. will be born in 2024 and reach age 15 in 2039, when the modelled 
period ends.   
 
 
3.  Sexual behaviour and risk of HIV acquisition 
 
Here we describe the approach to modelling sexual behaviour and HIV acquisition.  The basic approach is 
summarized in Figure S2.  The parameter values related to sexual behaviour were chosen such that they lead to 
a modelled HIV prevalence level over time as observed (Figure S1).  Sexual behaviour is characterized by two 
variables representing, respectively, the number of short term condomless sex partners and whether the person 
has a current long term condomless sex partners in the 3 month period.  The status of long term partners is 
tracked over time (i.e. if they are infected, diagnosed, on ART).  Short term partners are not tracked over time, in 
that if a person has a short term partner in time period t who is infected with HIV, this is independent of the 
probability that any short term partner in time t+1 is infected with HIV.   
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Figure S2.  Summary of modelling of sexual behaviour and HIV acquisition 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Determination of number of short term (condomless sex) partners at period t 
Numbers of short term partners in a given period was generated at random, according to which of four sexual 
behaviour groups the person was in for this period.  Changes in the sexual behaviour group from t-1 to t were 
determined by transition probabilities between 4 groups: (i) no short term condomless partners in 3 month 
period, (ii) 1 short term partner, (iii) medium number of short term partners, and (iv) high number of short term 
partners.  Transition probabilities 𝑝𝑔𝑖𝑗𝑎 of moving from partner group i at t-1 to partner group j at t are given by 
 
 𝑝𝑔𝑖𝑗𝑎 =
𝑓𝑔𝑖𝑗×𝑟𝑔𝑎
(𝑓𝑔𝑖1+∑ (𝑓𝑔𝑖𝑗∙𝑟𝑔𝑎)
4
𝑗=2 )
  
 
 
where g = 0,1 for males, females, respectively, and a = 1-10 for age groups 15-, 20-, 25-, 30-, 35-, 40-, 45-, 50-, 
55-, 60-, respectively.  Values of 𝑓𝑔𝑖𝑗  and 𝑟𝑔𝑎 are given in Tables S5 and S6, respectively, and if j=1 then 𝑟𝑔𝑎=1. 
 
Values of 𝑟𝑔𝑎  are modified at time t by a factor 0.2 if the subject has a current AIDS defining disease and by a 
factor ch_risk_diag_newp (with a value 0.83, informed by (Fonner et al 2012) if the subject is diagnosed with HIV 
(sqrt(ch_risk_diag_newp from 6 months after diagnosis).  In addition, there is a person-fixed modification factor 
(p_rred_p = 0.2).  For a proportion p_rred_p of men and 1.5.p_rred_p of women, values of 𝑟𝑔𝑎  are modified by a 
factor 0.1, to reflect the fact that a proportion of people experience only very low sexual risk activity in their life. 
 
Actual transitions between groups were determined by random sampling.  For the first two groups the number 
of partners in the period is given (i.e. no short term partners, 1 short term partner, respectively).  When a 
person was in the medium short term partners group the number of partners was determined by sampling from 
a Poisson(highsa), where highsa (= 4.4).  When in the high short term partners group the number of partners 
was determined by sampling from a Poisson(2) distribution and multiplied by the parameter swn (= 7).   
 
Determination of having a long term (condomless sex) partner at period t 
Note that only condomless sex partnerships are modelled.  Thus if a person has a long term partner but 
condoms are used on all occasions of sexual intercourse then this is not counted as having a long term 
condomless sex partner.    
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At each period, people with no current long term partner have age-dependent probabilities of having a new long 
term partner is dependent on parameter eprate and given by: age 15-24, p= eprate; age 25-34, p= eprate; age 
35-44, p= eprate/2; age 45-54, p= eprate/3; age 55-64, p= eprate/5 (eprate = 0.1). 
 
At the time a long term partnership is started, it is classified into 3 duration groups, each with a different 
tendency to endure.  The percent of people in each group is dependent on age and is shown in Table S7. 
 
At time period, t, for people with a long term partner, the probability of the condomless sex partnership 
continuing is (1-(0.25 / ch_risk_beh_ep)) if duration category is 1, is (1-(0.05 / ch_risk_beh_ep)) if duration 
category is 2, and (1-(0.02 / ch_risk_beh_ep)) if duration category is 3, where ch_risk_beh_ep is a parameter 
conveying the population level change in sexual behaviour with long term partners that occurs in 1995 
(ch_risk_beh_ep = 0.4).   Further, this probability is reduced by a factor  ch_risk_diag in the 3 month period after 
a partner’s diagnosis, if a partner has HIV and is diagnosed.  (ch_risk_diag = 0.7).   
 
Note also that levels of sexual behaviour, in terms of numbers of short term partners and the probability of a 
long term partner are essentially determined by the levels of such sexual behaviour required in order to produce 
an epidemic as described, given rates of transmission with condomless sex partners.  Sexual behaviour tends to 
be under-reported particularly in women and higher levels of behaviour have to be assumed both to be 
consistent with levels of risk behaviour reported in men, and to generate an epidemic of the proportions 
observed (e.g. Gregson 20022, Johnson 2009).  Nonetheless, reported sexual behaviour, particularly in terms of 
differences by age in males and females have been referred to (e.g. Zimbabwe DHS 2004, Zimbabwe DHS 2011). 
 
 
Population level change in sexual behaviour 
There is assumed to be a general average reduction in condomless sex after 1995, reflecting the reductions 
observed over the period from around this date (Gregson 2010, Halperin 2011). 
 
 
Determination of number of short term (condomless sex) partners who are HIV infected at time t 
For each short term partner that a subject has at time t, the probability that the partner is infected is calculated.  
This is dependent on the prevalence of HIV in those of the opposite gender, taking consideration of age mixing.  
If the subject is of gender g and age group a, then for each short term partner the first step is to determine by 
sampling at random, the age group of the short term partner, 𝑎newp (in fact, for simplicity, all short term 
partners at time t are assumed to be in this same age group).  The gender and age mixing probabilities used are 
given by values in Table S8. 
 
Then, for the given partner (of gender 1-g and age group anewp), the risk that the partner is infected is then given 
by 
ℎ𝑔𝑎𝑡 =
∑ 𝐿(𝑡−1)
inf
𝑎newp,(𝑔−1)
∑ 𝐿(𝑡−1)𝑎newp,(𝑔−1)
 
where 𝐿(𝑡−1)
inf  is the total number of infected short term partners at time (t-1), and 𝐿(𝑡−1) is the total number of 
short term partners at time t-1. The numerator is therefore the total number of infected short term partnerships 
of the opposite gender in age group anewp. 
 
Since we assume that all short term partners at time t are in this same age group, the total number of infected 
short term partners that the subject has at time t, 𝐿𝑡
inf, is then given by  
 
𝐿𝑡
inf = Min(Poisson(ℎ𝑡 ∙ 𝐿𝑡), 𝐿𝑡) 
 
The distribution of numbers of partners by age and gender is shown in Table S9.   
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Determination of probability that a long term partner is HIV infected at time t 
𝐸𝑡
inf indicates whether the subject has a long term (condomless sex) partner who is infected (𝐸𝑡
inf = 1 if infected, 
else 𝐸𝑡
inf = 0). A long term partner at time t can be infected either because (i) a new long term partnership has 
been formed and the partner was already infected, (ii) because a long term partner at t-1, which has remained a 
long term partner at time t, has become infected, or (iii) because an infected long term partner has remained as 
a long term partner. 
 
For (i): 
 
𝐸𝑡
inf = 1  if  𝐿(𝑡−1)
inf ≥ 1 (i.e. if the subject had a short term partner at time t-1 who was infected then it is 
assumed that the new long term partner is infected)  
 
For (ii): 
 
The probability that a long term partner of a subject of age group a and gender g becomes infected is derived 
from the HIV incidence at t-1 for age group a (i.e. the same age group) and gender 1-g, 𝑖𝑎(1−𝑔)(𝑡−1) among the 
sexually active population, either with a long term partner or at least one short term partner (which is given by 
the number of subjects newly infected in age group at time t-1 divided by the number of HIV-uninfected 
subjects in age group at t-1,  who had condom-less relationships, either long or short term) 
 
{
𝐸𝑡
inf = 1, 𝑈 < 𝑖𝑎(1−𝑔)(𝑡−1)  where 𝑈 randomly sampled from 𝑈𝑛𝑖𝑓𝑜𝑟𝑚(0,1)
𝐸𝑡
inf = 0, otherwise
 
 
In order to maintain balance, for each gender, between the number of uninfected people with a long term 
partner who is infected, and the number of infected people with a long term partner who is uninfected, this 
incidence 𝑖𝑎(1−𝑔)(𝑡−1) is modified at time t dependent on the degree of balance at time t-1.   
 
 
For (iii):  
 
If 𝐸(𝑡−1)
inf = 1  and  𝐸𝑡 ≥ 1  then assign  𝐸𝑡
inf = 1  
 
 
Determination of the risk of infection from a short term partner 
For each HIV infected short term partner of a subject of gender g and age group a the viral load group, v, of the 
partner is obtained by sampling from the viral load distribution of those of the opposite gender.  Thus we 
sample from Uniform(0,1), where the probability of the partner having viral load in group v is given by   
 
∑ 𝐿(𝑡−1)
inf
𝑣
∑𝐿(𝑡−1)
inf
 
 
where the numerator is the total number of short-term partnerships had by infected people  in viral load group 
v and the denominator is the total number of short-term partnerships had by infected people (in any viral load 
group).   
 
Viral load groups are:  
 
(1) < 2.7 log cps/mL 
(2) 2.7-3.7 log cps/mL 
(3) 3.7-4.7 log cps/mL 
(4) 4.7-5.7 log cps/mL 
(5) > 5.7 log cps/mL  
(6) primary infection.    
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Once the viral load group, v, of the infected partner is determined, the probability, tv, of the subject being 
infected by the partner is then given according to: t1 = Normal (tr_rate_undetec_vl,0.000025
2), t2 = Normal 
(0.01,0.00252), t3 = Normal (0.03,0.0075
2), t4 = Normal (0.06,0.015
2), t5 = Normal (0.1,0.025
2), t6 = Normal 
(tr_rate_primary,0.0752).  These are based on Hollingsworth et al (2008) and are the rates for a longer term 
partner.  The transmission rate for a short term partner is multipled by fold_tr_newp (0.35) due to the assumed 
lower number of sex acts.   These probabilities are increased by fold_change_w-fold (= 1.5) for female subjects 
aged > 20, by 2-fold for female subjects aged < 20, and by fold_change_sti-fold (= 3.0) if the person has an 
existing STI (risk of a new STI in any one three month period is given by the number of short term condomless 
partners / 20 (or 1 if > 20 short term partners)) (Cohen et al 1998, Nicolosia 1994). 
 
We assume that super-infection can occur(i.e. a person can be reinfected with HIV with consequent risk of 
acquiring new mutations).  
 
Realization of whether the subject is infected by each short term partner is determined by sampling from 
Uniform(0,1). 
 
 
Determination of the risk of infection from a long term partner 
Infected long term partners at time t are classified by whether they are in primary infection (if infection occurred 
at t-1), whether they are diagnosed with HIV, whether they are on ART, and whether their current viral load is < 
2.7 cps/mL or not.  The proportion of long term partners with HIV who have HIV diagnosed at time t, 𝑝𝑡
e,diag, is 
determined with reference to the difference, 𝑑(𝑡−1)
e,diag , in the proportion of subjects with HIV who are diagnosed, 
𝑇(𝑡−1)
diag
𝑇(𝑡−1)
inf  and 𝑝(𝑡−1)
e,diag ;  
 
i.e. 𝑑(𝑡−1)
e,diag =
𝑇(𝑡−1)
diag
𝑇(𝑡−1)
inf − 𝑝(𝑡−1)
e,diag  
 
 
where 𝑇(𝑡−1)
diag  is the total number of subjects diagnosed with HIV at time t-1and 𝑇(𝑡−1)
inf  is the total number of 
subjects with HIV (diagnosed and undiagnosed) at time t-1.   
 
 
{
 
 
 
 if 0 < 𝑑(𝑡−1)
e,diag ≤ 0.05  then 𝑝𝑡
e,diag = 0.4
if 0.05 < 𝑑(𝑡−1)
e,diag ≤ 0.10 then 𝑝𝑡
e,diag = 0.5
if 0.10 < 𝑑(𝑡−1)
e,diag ≤ 0.15  then 𝑝𝑡
e,diag = 0.9
if 0.15 < 𝑑(𝑡−1)
e,diag   then 𝑝𝑡
e,diag = 0.95
 
 
The proportion of those diagnosed who are on ART, and the proportion of those on ART who have viral load < 
2.7 log cps/mL are determined in a similar manner.  In this way the proportions diagnosed with HIV, on ART, and 
with current viral load is < 2.7 log cps/mL are kept similar for the long term partners as in the simulated subjects 
themselves. 
 
Risk of infection from a long term infected partner is determined by Normal (tr_rate_primary, 0.0752) if the 
existing partner is in primary infection (ie. infected at t-1), Normal (tr_rate_undetec_vl, 0.0000252) if the existing 
partner has viral load < 2.7 log cps/mL, and Normal (0.05, 0.01252) otherwise. 
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Transmitted resistance: overview 
The modelling of transmission of drug resistance is summarized in Figure S3.  The presence or not of resistance 
mutations does not influence the risk of transmission (i.e. virus with resistance mutations present is assumed 
equally transmissible as virus without such mutations, for a given viral load).  Resistance is modelled in terms of 
the presence or absence of mutations specific to the drugs in use.  Distinction is made for each mutation as to 
whether it is only present in minority virus (if the patient has a mutation present but has stopped drugs that 
select for that mutation), so the mutation is assumed not transmissible, or if it is present in majority virus, and 
hence the mutation is assumed transmissible.  The probability that resistance mutations present in majority 
virus of the source partner are transmitted to the newly infected person is dependent on the specific mutation.  
Once a resistance mutation is transmitted to the new host it is assumed to have a certain probability of being 
lost from majority virus over time (Castro 2013).   Even after being lost from majority virus,  it is assumed to 
remain in minority virus and is selected back as majority virus if an antiretroviral drug selecting for that mutation 
is initiated.   We also consider the possibility of a person who is already infected become super-infected, 
including with drug resistant HIV (Smith 2005), although there is assumed to be at most a 20% chance that a 
person super-infected by a person with HIV resistance then has virus with those resistance mutations as a result. 
 
Figure S3.  Overview of modelling of transmission of drug resistance. 
 
 
 
 
 
 
 
 
 
 
 
Transmitted resistance: details 
The viral load group of the person who infected the subject is known, as indicated above. For a subject infected 
by a person in viral load group v the probability of a resistance mutation being present in the infected person is 
given by  
 
∑ 𝐿(𝑡−1)
inf
𝑣,  and mutation present
∑ 𝐿(𝑡−1)
inf
𝑣
 
 
where ∑  𝑣, and mutation present is the sum over all partnerships had by HIV-infected people in viral load group v for 
whom a resistance mutation is present in majority virus and ∑  𝑣 is the sum over all HIV-infected subjects in viral 
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load group v.  Again, realization of whether the subject is infected by a person with at least one resistance 
mutation in majority virus is determined by sampling from Uniform(0,1). 
 
For subjects infected from a source partner with a resistance mutation, the probability that a specific mutation, 
m, is present in the source is given by   
 
∑ 𝐿(𝑡−1)
inf
mutation 𝑚 present 
∑ 𝐿(𝑡−1)
inf
mutation present 𝑣
 
 
Where ∑  mutation 𝑚 present is the sum over all HIV-infected subjects with mutation m present in majority virus and 
∑  mutation present is the sum over all HIV-infected subjects with at least one resistance mutation in majority virus. 
 
If a given resistance mutation, m, is present in the source partner, the probability that the mutation is both 
transmitted and survives in the subject (i.e. that its presence will affect future response to drugs for which the 
mutation confers reduced sensitivity) is mutation specific, as shown in Table S10. 
 
We consider uncertainty in the extent to which transmitted resistance mutations are effectively immediately 
lost (even from minority virus) by sampling from a distribution for parameter res_trans_factor  (= 0.6, informed 
by fitting of a model of HIV in MSM to UK data (Phillips et al PLOS ONE 2013).    
 
Loss from majority virus of transmitted mutations 
 
There is a probability per 3 months of loss of persistence of transmitetd mutations from majority virus to 
minority virus (same for each mutation) rate_loss_persistence 0.04, again informed by fitting of a model of HIV 
in MSM to UK data (Phillips et al PLOS ONE 2013).    
 
Model outputs relating to sexual behaviour and transmission  
Table S9  shows the proportion of people with at least one (at least two) condomless sex partner in the past year 
by HIV status and year.  Table S11  shows the proportion of new infections that have been acquired from a 
person in primary HIV infection by year, and the proportion of new infections that have been acquired from a 
long term partner by year. Table S13  shows HIV prevalence by age and gender and calendar year.    
 
Table S5.  Values of 𝑓𝑔𝑖𝑗   (values determining probability of transitioning between short term partner risk 
behaviour groups) 
-------------------------------------------------------------------------------------------------------------------- 
Short term partners  Short term partners group in period t 
group in period t-1 0  1   medium  high 
       (Poisson (Poisson 
       mean highsa*) mean 2  x swn*) 
-------------------------------------------------------------------------------------------------------------------- 
Males 
0   0.89  0.08  0.03  0.00 
1   0.80  0.15  0.05  0.00  
medium  0.35  0.27  0.38  0.00 
high   ---  ---  ---  --- 
Females 
0   0.93  0.05  0.02  0.00025     
1   0.86  0.11  0.03  0.0005 
medium  0.54  0.08  0.38  0.001 
high    0.05  0.05  0.10  0.800 
----------------------------------------------------------------------------------------------------------------------- 
* highsa = 4.4, swn = 7 
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Table S6.  Values of 𝑟𝑔𝑎  (factor determining relative level of sexual risk activity) 
------------------------------------------------------------------------------------------ 
Age group   Males  females 
(a=1,10)   (g=1)  (g=2) 
------------------------------------------------------------------------------------------ 
15-    0.60  1.60 
20-    0.60  1.60 
25-    1.00  1.00 
30-    0.80  0.80  
35-    0.65  0.50 
40-    0.50  0.35 
45-    0.40  0.10 
50-    0.35  0.05 
55-    0.25  0.04 
60-    0.15  0.02 
------------------------------------------------------------------------------------------ 
 
 
Table S7.  Percent of newly formed long term partnerships classified into each of three duration groups, each of 
which has a different tendency to endure (higher class, more durable).   
 
Age  1   2   3 
----------------------------------------------------------------------------------------------- 
15-44  30%   30%   40% 
45-54  30%   50%   20% 
55-64  30%   70%   0% 
----------------------------------------------------------------------------------------------- 
 
 
Table S8.  Sexual mixing by age and gender. The proportion of short term partnerships formed by men in age 
group am which are with females of age group af and the proportion of short term partnerships formed by 
females in age group af which are with men of age group am.        
 
   Females  
   Age group (af) 
Males 
Age group (am)  15-24 25-34 35-44 45-54 55-64 
---------------------------------------------------------------------------------------- 
15-24   0.865 0.11 0.025 0.00 0.00  
25-34   0.47 0.43 0.10 0.00 0.00 
35-44   0.30 0.50 0.20 0.00 0.00 
45-54   0.43 0.30 0.23 0.03 0.01 
55-64   0.18 0.18 0.27 0.27 0.10 
---------------------------------------------------------------------------------------- 
   Males  
   Age group (am) 
Females 
Age group (af)  15-24 25-34 35-44 45-54 55-64 
---------------------------------------------------------------------------------------- 
15-24   0.43 0.34 0.12 0.10 0.01  
25-34   0.09 0.49 0.30 0.10 0.02 
35-44   0.03 0.25 0.34 0.25 0.13 
45-54   0.00 0.00 0.05 0.25 0.70 
55-64   0.00 0.00 0.00 0.10 0.90 
---------------------------------------------------------------------------------------- 
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Table S9.  Sexual risk behaviour  in 1990 and 2000 (after behaviour change) 
 
1990 (start of epidemic)  % with > 1 (>2; > 10; >50) condomless sex partners (short or long term)  
     in past year 
 
Age group    Males    Females 
------------------------------------------------------------------------------------------------------------------------------------------------- 
15-      85% (66%;10%;0%)   87% (77%;21%;0.5%) 
25-     96% (84%;17%;0%)   94% (77%;18%;0.2%)  
35-     94% (77%;12%;0%)  88% (60%;9%;0.2%) 
45-     91% (68%;9%;0%)   70% (23%;1%;0.05%) 
55-     85% (57%;6%;0%)   64% (19%;1%;0%) 
------------------------------------------------------------------------------------------------------------------------------------------------- 
 
2000      % with > 1 (>2; > 10; >50) condomless sex partners (short or long term)  
     in past year 
 
Age group    Males    Females 
------------------------------------------------------------------------------------------------------------------------------------------------- 
15-      48% (55%;2%;0%)   55% (17%;5%;0.15%) 
25-     71% (64%;4%;0%)   64% (36%;58%;0.05%)  
35-     58% (47%;4%;0%)  47% (25%;2%;0.07%) 
45-     52% (25%;2%;0%)   25% (21%;0.05%;0%) 
55-     40% (17%;2%;0%)   17% (15%;0%;0%) 
------------------------------------------------------------------------------------------------------------------------------------------------- 
 
 
Table S10.  Table of probabilities that for a given mutation present in the source partner the mutation is both 
transmitted and survives in the subject.  (based on evidence from studies comparing distribution of resistance 
mutations between treated and antiretroviral naïve populations; (e.g. Corvasce et al 2006, Turner et al 2004) 
and modelling of HIV in MSM in the UK (Phillips PLOS ONE 2013). 
 
------------------------------------------------------------------------- 
M184V      0.52 
K65R      0.52 
L74V      0.70 
Q151M      0.70 
Thymidine analogue mutations (TAMS)  0.70 
NNRTI mutations (K103N, G190A, Y181C) 0.88 
PI mutations      0.70 
-------------------------------------------------------------------------- 
 
 
Table S11.  Proportion of people with at least one (at least two) condomless sex partner (including long term 
partner) in the past year by HIV status and year using modal values for parameters.     
 
  1990  1995  2000  2005  2010  2014 
----------------------------------------------------------------------------------------------------------------------------------------------------- 
HIV+  98% (89%) 87% (56%) 64% (29%) 60% (29%) 55% (27%) 63% (37%) 
HIV + diagnosed ---  ---  53% (23%) 54% (23%) 51% (24%) 60% (33%) 
HIV-  86% (64%) 71% (38%) 46% (18%) 46% (19%) 49% (21%) 59% (32%) 
----------------------------------------------------------------------------------------------------------------------------------------------------- 
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Table S12.  Origin of new infections for one example epidemic, based on using modal values for parameters. This 
shows the proportion of new infections that have been acquired from a person in primary HIV infection by year, 
and the proportion of new infections that have been acquired from a long term partner by year.  For infections 
from people with primary infection, there are little data from sub-Saharan Africa to our knowledge.  For 
proportion of people infected by a long term partner, compare with Dunkle et al 2008. 
 
     Status of source partner 
 
   Primary infection     Long term partner 
   1990 2000 2010   1990 2000 2010 
----------------------------------------------------------------------------------------------------------------------------- 
Males   87% 39% 28%   27% 50% 47% 
Females  88% 44% 36%   25% 45% 42% 
----------------------------------------------------------------------------------------------------------------------------- 
 
 
Table S13.  HIV prevalence age 15-49 by gender and prevalence by age and gender 2015 
 
     Males    Females 
------------------------------------------------------------------------------------------------------------------------------------------------- 
1990     12.3%    13.2% 
1995     26.4%    34.4%  
2000     21.5%    30.1%  
2005     15.4%    23.9%     
2010     11.8%    20.2% 
2014     10.1%    17.6%     
------------------------------------------------------------------------------------------------------------------------------------------------- 
 
Prevalence by age 2014    
-------------------------------------------------------------------- 
15-25     2.8%     
25-35     13.8% 
35-45     33.5%  
45-55     28.2% 
55-65     10.9% 
-------------------------------------------------------------------- 
 
 
 
  
      
 35 
4.  Natural history of HIV infection 
 
Figure S4 gives an overview of the modelling of HIV natural history.  The model of the natural history of HIV and 
the effect of antiretroviral therapy has been derived previously and compared with a range of observed data 
(see Phillips et al Lancet 2008, AIDS 2011, Nakagawa et al 2012, 2015 and associated supplementary material).  
Below we set out the structure of the model and explain what parameters represent.   
 
 
Figure S4.  Overview of modelling of natural history of HIV infection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Determination of changes in viral load and CD4 count 
Initial log10 viral load (Vset) is sampled from Normal(4.0,0.5
2)  
 
This viral load (Vset) is assumed to be that reached after primary infection.  It is not used to determine the risk of 
transmission in primary infection itself.    
 
Initial CD4 count, modelled on the square root scale, is partially dependent on initial viral load and given by  
 
Square root CD4 count = mean_sqrtcd4_inf (= 27.5) - (1.5 x Vset) + Normal(0,2
2) – ((age – 35) x 0.05) 
 
Initial virus is assumed to be R5-tropic.  Shift to presence of X4 virus is assumed to depend on viral load.  
Probability of a shift per 3 months is given by  10v x 0.0000004, where v is the current log10 viral load. 
 
Viral load change (vc) from period t-1 to period t (i.e. in 3 months) is given by  
 
Vc(t-1( = (gx x 0.02275 + Normal(0, 0.052) + ((age(t-1) - 35) x 0.00075)   
 
gx=1   viral load at t (v(t)) = v(t-1)+ vc(t-1) 
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CD4 count changes from period t-1 to t are dependent on the current viral load (i.e. viral load at time t-1) and 
are given by sampling from a Normal distribution with standard deviation sd_cd4  and mean fx (= 1.0) times the 
values as follows 
 
 
Viral load Change in   
at t-1  square root  
  CD4 count 
  (per 3 mths) 
----------------------------------------------- 
< 3.0  +0.000  
3-0  +0.022 
3.5-  +0.085 
4.0-  - 0.400 
4.5-  - 0.400 
5.0-  - 0.850 
5.5-  - 1.300 
6.0-  - 1.750 
----------------------------------------------- 
 
 
The change additionally is affected by the current age as follows: 
 
People with X4 virus present experience an additional change in square root CD4 count of -0.25. 
 
These estimates were derived based on consideration of evidence from natural history studies (Pantazis 2005,  
Sabin JAIDS 2000, Hubert J-B 2000, O'Brien 1998, Henrard  1995, Lyles 2000, Touloumi 2004, Mellors 1997, Koot 
1993) and were selected in conjunction with other relevant parameter values to provide a good fit to the 
incubation period distribution.  Differences that have been found in initial viral load by sex, age and risk group 
are not currently incorporated in the model.  
 
 
Table S14.  Incubation period by age.  Kaplan-Meier percent with WHO 4 Event.  Compare with Darby et al 1996. 
 
Age at infection  Years from infection 
 
   1  3 5 10 15  20  
------------------------------------------------------------------------------------------------ 
15-   0.6% 4% 14% 50% 75% 89% 
25-   1.1% 2% 23% 67% 88% 97% 
35-   2.1% 13% 34% 82% 97% 100% 
45-   3.7% 21% 54% 93% 100% 100% 
55-   1.4% 24% 59% 96% 100% 100% 
------------------------------------------------------------------------------------------------ 
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5.  HIV testing and diagnosis of HIV infection 
 
HIV testing was assumed introduced in 1996. At that time we assumed 20% of the population were resistant to 
be tested for HIV unless symptomatic and this decreased linearly to 5% by the end of 2010.  In the model this 
group has no possibility of getting tested for HIV unless symptomatic.  Limited data are available to inform this 
parameter (proxy variables are the proportion who reported never being tested for HIV and, more precisely, the 
proportion who refuse HIV testing), nevertheless we considered it important to take this into account, given the 
evidence that not everyone accepts HIV testing for various reasons.  The level of acceptability of provider 
initiated HIV testing and counselling (PITC) in resource limited settings is extremely variable from levels of 99%, 
observed in inpatients in Uganda (Wanyenze 2011) to 31% among outpatients in South Africa (Bassett 2007).   
Among pregnant women the level of acceptability of PITC seems to be higher, varying from 76 to 99.9% (Hensen 
2012), while the estimated acceptability of home-based counselling and testing has been estimated in  a meta-
analysis to be 83% (Sabapathy 2012). This variability seems to be related mainly to the quality of the 
intervention delivered and calendar time.   Acceptability seems to have increased over time due to the reduction 
in stigma and higher availability of ART, therefore we thought it was reasonable to assume a decline in the 
proportion resistant to be tested for HIV down to 5% in 2010.  
For the remainder  of the population (non-resistant to HIV testing), increasing gender and age-specific rates of 
HIV testing (for the 1st time and for repeat testing) since 1996 were assumed, to reflect the level of testing 
observed in the DHS (DHS Zimbabwe). Pregnant women  experience an additional probability of being tested in 
the ANC, which increases over calendar year (DHS Zimbwabwe). 
For people who have never had condomless sex, a 3-fold reduction in the rate of testing was assumed.  This has 
been observed in the Zimbabwe DHS where people who reported never having had sex (whether with or 
without condom) are less likely to test for HIV.  Comparisons of modelled output with data from DHS are shown 
in Figures S5 and S6. 
People with acute symptoms (WHO stage 4, 3 or active TB) are assumed to have a higher chance of testing for 
HIV in that 3 month period and a higher chance of being linked to care once diagnosed. In 2015 the probability 
of testing as a result of symptoms was 0.8, 0.48 and 0.12, respectively, for people with a WHO stage 4 event, 
tuberculosis and WHO stage 3 event. 
In this application the model does not distinguish between how HIV testing is delivered.  Further details of 
calibration of testing rates to Zimbawe and of modelling of self-testing are given in Cambiano et al 2015. 
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Figure S5. Gender and age-specific proportion ever tested for HIV predicted by the model and observed in DHS 
surveys 
 
Figure S6. Gender and age-specific proportion tested in the last year, predicted by the model and observed in 
the DHS surveys 
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6.  Modelling the effect of ART 
 
The structure of the relationship between ART adherence, viral load, development of resistance, CD4 count and 
risk of death is modelled is illustrated in Figure S7 below.  The adherence level - the determination of which is 
described in detail below - influences the risk of acquisition of new mutations as well as having a direct effect on 
the viral load and CD4 count.  Acquisition of resistance mutations impacts on the number of fully active drugs in 
the current regimen.  This, in turn, is a further determinant of the risk of new mutations arising.  Failure of the 
current line of ART is determined by CD4 count or viral load or clinical disease, depending on the monitoring 
strategy, and this triggers a switch to the next line of ART (if assumed available, and often with a delay), which 
leads to the number of active drugs again returning to 3 or more if on boosted PIs.  The following sections 
provide further details, including how adherence levels are determined and how they influence the viral load, 
risk of resistance and the CD4 count.   We also explain the modelling of ART interruption and loss to follow-up.   
We provide references to papers that have been used to inform the approach.  It should be noted though that 
parameter values used in the model are rarely extracted directly from any one paper, they are values that are 
arrived at based on their ability to generally reproduce outputs that are consistent with observed estimates, as 
illustrated below.   
 
Figure S7.  Overview of the modelling of the effect of ART, highlighting the role of adherence. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Initiation of ART 
 
ART initiation in diagnosed people before 2010 is determined by a measured CD4 count < 200 or the 
development of a WHO 4 event.  From 2011 this is determined by a CD4 count < 350 and from 2015 by a CD4 
count < 500 or pregancy (option B+).  We assume that CD4 counts are monitored at 6 monthly intervals for 
those who are in pre-ART care.   
 
 
Switch to second line after failure of first line ART 
 
Whichever the criterion for the need to switch to second line ART is determined, the probability of switching per 
3 month period after the criterion is met is pr_switch_line (0.001 before 2015, increasing after 2015 as described 
in main manuscript). The switch rate is likely to vary substantially by setting (Fox 2012; Johnston 2012).  In 
several settings, including Zimbabwe, the proportion of people who have started second line ART is consistent 
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with a value for  pr_switch_line of below 0.1 (e.g. Lesotho, Malawi) (personal communications Zimbabwe 
MoHCC; Government of Malawi Ministry of Health, Integrated HIV Program Report, Oct-Dec 2014). 
 
 
Adherence pattern  
 
The model specifies a current adherence level (i.e. for the current 3 month period) for people on ART.  Given 
that the model updates in 3 month time periods the adherence level in a given 3 month period has to effectively 
be considered as the average adherence over the period.   The determination of this is described below.  
Interruption of ART for periods of duration 3 months is considered separately (and explained in subsequent 
sections below).    
 
Consistent with evidence that people tend to have different tendencies to adhere (Cambiano 2010a;Carrieri 
2001;El-Khatib 2011;Genberg 2012;Glass 2010;Kleeberger 2004;Lazo 2007;Levine 2005;Mannheimer 
2002;Meresse 2014;Osterberg 2005), adherence is modelled using two components.  Each patient has a certain 
greater or lesser tendency to adhere (adhav, measured on a scale of 0-100%) but their actual adherence in a 
given period varies over time, both at random and according to the presence of symptoms (with drug toxicity or 
presence of WHO stage 4 disease leading to a decrease in adherence) and there is an effect of a tendency for 
increasing adherence with age.   Adherence in a given 3 month period (adh{t}) is measured on a scale of 0 to 
100%. adhvar is the standard deviation representing the within-person period-to-period variability over time.  
Thus, adherence at any one period (adh{t}) is determined as follows (although with modifications explained 
below):- adh(t) = adhav + Normal(0,adhvar2).   The distribution of the values of adhav and adhvar is specified as 
follows and as illustrated in Figure S8: 
 
5% probability    adhav   =  50%   adhvar  =  0.2     
10% probability   adhav   =  80%  adhvar  =  0.2       
65% probability   adhav   =  90%  adhvar  =  0.05     
20% probability   adhav   =  95% adhvar =  0.05     
 
Figure S8.  Illustration of adherence pattern assumptions.  5% of the population have the adherence as shown in 
the top left, 10% as shown in the top right, etc.  While adherence is generally high in the majority of people on 
ART (hence the high proportion of people on ART with viral suppression), most probably experience at least 
some periods of poorer adherence (e.g. see (Muyingo 2008)). 
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This distribution of adherence is primarily determined by the adherence levels required for the model outputs to 
mimic observed data.  This includes data on rates of resistance development and virologic failure and also data 
on the proportion of patients at first virologic failure who have no resistance mutations present (Bangsberg 
2004;Bangsberg 2006b;Hamers 2011;Hassan 2014;Hoffmann 2014;Kobin 2011;Li 2014;Mackie 
2010;Mannheimer 2002;Meresse 2014;Rosenblum 2009;Tran 2014;Usitalo 2014;von, V 2013).  It is clear from 
such data in more recent years that the great majority of patients who started ART with 3 or more drugs are 
sufficiently adherent that virologic failure rates are low (and so resistance accumulation is also likely to be low) 
(El-Khatib 2011;Johannessen 2009).  
 
Figure S9: Risk of virologic failure while on ART according to adherence level 
 
 
 
Figure S10: Risk of NNRTI resistance with virologic failure while on ART, according to adherence level 
 
 
The distribution of adherence over the first year of ART has been compared with data from a large programme 
in Zambia (see Figure S11; (Chi 2009)).  The degree to which outputs on viral load at one year from start of ART is 
shown in Figure S12.  These are reconstructed outcomes for all people who have initiated ART in Zimbabwe (the 
overall mean CD4 count at initiation is 145 /mm3). Figures S13 and S14 compare Kaplan Meier estimates of time 
to virologic failure and resistance, respectively, between the model and observed data, in the latter case from 
the UK due to the lack of data from sub-Saharan Africa. Figure S15 illustrates the proportion of people with 
resistance (amongst those on ART with non-suppressed viral load) and corresponds to estimates from the large 
WHO resistance surveillance. 
 
 
  
      
 42 
Figure S11.  Distribution of average adherence level over first year of ART (for those on ART at 1 year). 
 
 
 
 
 
Figure S12.  (a) Percent of people alive at given time points from start of ART who have viral load suppression 
and (b) percent of people alive and on ART at given time points .from start of ART who have viral load 
suppression (WHO Resistance Surveillance Report 2012(WHO 2012)). 
 
 (a)  
 
 
(b) 
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Figure S13.  Kaplan Meier estimates of risk of virologic failure while on ART, by time from start of ART. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S14.  Kaplan Meier estimates of risk of NNRTI resistance with virologic failure while on ART, by time from 
start of ART (Cozzi-Lepri 2010).  
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Figure S15.  Of people with viral load > 500 at 1 year from start of ART, percent who have NNRTI drug resistance 
(WHO Resistance Surveillance Report 2012(WHO 2012)). 
 
 
 
 
Effective adherence  
 
We also considered the concept of effective adherence, which reflects predicted adequacy of drug levels, 
whereby for those on regimens that do not include an NNRTI the effective adherence is as the adherence itself, 
but for those on NNRTI-containing regimens the effective adherence is the adherence + add_eff_adh_nnrti (base 
value 0.1), reflecting the long half life of NNRTI drugs (Cheeseman 1993) which is an advantage as it means such 
regimens are more forgiving of periods of poor adherence (Bangsberg 2004;Bangsberg 2006a;Bangsberg 
2006b;Gardner 2009;Gross 2008;Kobin 2011;Meresse 2014;Parienti 2007). Additionally, it is assumed that 
patients on ART are susceptible to occasional (rate 0.02 per year) severe temporary drops in drug level (i.e. 
effective adherence level), leaving them susceptible to viral rebound (but with low risk of resistance as the 
effective adherence drop is so profound).  This phenomenon is assumed to be 3 times more frequent among 
those on protease inhibitor regimens than in those on other regimens.  This latter assumption is the only 
plausible means (at least within our model framework) to explain why virologic failure occurring on boosted 
protease inhibitor regimens often occurs in the absence of resistance (Hill 2013).  
 
Effect of viral load measurement above 1000 cps/mL on adherence 
 
Various factors can influence adherence, including the initial measurement of viral load > 1000 copies/mL which 
is assumed to lead to an increase in adherence in 70% of people as a result of targeted adherence intervention; 
this is consistent with data showing that a high proportion of people with measured viral load > 1000 copies/mL 
who undergo an adherence intervention subsequently achieve viral suppression without a change in ART (Orrell 
et al 2007, Hoffman et al 2009, Hoffman et al 2013, Rutstein et al 2015)  and broadly consistent with a meta-
analysis (Bonner et al 2013).   Although the appropriate duration to assume for this effect is uncertain (Hoffman 
et al 2013), the impact of adherence interventions has often been shown to diminish with time (Bärnighausen et 
al  2011).   Based on this overall body of data, we assume that the adherence intervention is effective only the 
first time it is performed and that for 40% the effect is permanent (i.e. 70% x 40%= 28% of those with a viral load 
>1000), but that in the remaining 60% (i.e. 70% x 60% = 42% of those with viral load>1000) it lasts only 6 
months.   
Interruption of ART  
 
People can interrupt ART, and this may be due to not continuing with clinic visits (disengagement, modelled as 
simultaneous interruption and loss) but ART can be interrupted also in those still attending clinical visits.  The 
basic rate of interruption due to patient choice is rate_int_choice (base value: 0.02) - this rate is greater in 
people with current toxicity (2-fold) (note that in addition to this increased risk of interruption with current 
toxicity, there is assumed to be some substitution of drugs causing toxicity with available alternatives and a 
greater rate of interruption in patients with a greater tendency to be non-adherent (1.5-fold if adherence 
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average adhav 50 – 79% and 2-fold if adherence average adhav < 50%).  In a systematic review, drug toxicity, 
adverse events and side effects  have been found to be the most commonly given reasons for drug 
discontinuation  (Kranzer 2011).     
 
The rate of interruption also reduces with time on ART, decreasing after 2 years.  Evidence suggests that rates of 
discontinuation does decrease over time ((Kranzer 2010;Tassie 2010;Wandeler 2012) although the point at 
which the risk lowers might be somewhat earlier than 2 years.   If adherence average (adhav) > 80% then there 
is a 30% chance that interruption coincides with interrupting/stopping visits to the clinic, if 50 <= adhav < 80% 
then 45% chance, if adhav < 50% then 60% chance.   This is due to an assumption that factors leading to poor 
adherence are also likely to be associated with interruption.    The rate of interruption and disengagement with 
care is likely to vary by setting.  Figure S16 shows a comparison between modelled and observed (from a study 
by Kranzer et al. (Kranzer 2010)). Kaplan Meier estimates of the percent of people having interrupted or 
discontinued ART by time from ART initiation. 
 
Figure S16.  Percent who have interrupted or discontinued ART by time from initiation.  
 
 
  
 
Interruption of ART without clinic/clinician being aware 
 
It is known that in some instances people on ART have such poor adherence that they have in fact interrupted or 
stopped ART entirely but, in the same way that the clinician is not always aware of the true adherence level, 
they are also not always aware when the person has completely interrupted ART.  This means that the clinician 
(in the absence of a resistance test) may think a patient is virologically failing, because viral load is high, when in 
fact this is due to interruption rather than resistance.  This can be seen from studies on people with virologic 
failure in which a proportion have no identified resistance mutations (Hamers 2011;Hoffmann 2009;Wallis 
2010).  Thus, when a person interrupts ART (but remains under care) we introduce a variable that indicates 
whether the clinician is unaware.  clinic_not_aw_int_frac (base value 0.6).  This value of 0.6 was chosen to 
produce realistic model outputs for the proportion of people with virological failure who have resistance.  If a 
patient has interrupted ART with the clinician unaware then not only is the patient (wrongly) classified (by the 
clinician) as virologically failing (if viral load has been measured), but a switch to second line can occur.  Figure 
S15 compares the proportion of people with resistance between our model and WHO survey data. 
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Re-initiation of ART after interrupting in patients still under clinic follow-up 
 
For patients who have interrupted ART due to choice but are still under clinic follow-up, the probability of 
restarting ART per 3 months in the base model is prob_restart (base value 0.2).   This probability is increased 3-
fold if a new WHO 3 condition has occurred at t-1, and 5-fold if a new WHO 4 condition has occurred at t-1 since 
occurrence of clinical disease in a person seen at clinic is likely to prompt ART re-initiation. This will vary by 
setting but is informed by studies showing that of people who have initiated ART who are still seen at clinic a 
very high proportion are on ART at 12 months from start of ART (McMahon 2013).  Kranzer et al found a rate of 
restarting ART amongst those that interrupted or discontinued of 21 per 100 person-years but this figure is an 
overall figure which includes in the denominator those who are not attending the clinic (loss to follow-up and 
return to care are described below).  The equivalent figure, produced as an output from the model is 19 per 100 
person-years.   
 
Interruption due to drug stock-outs 
 
The basic rate of interruption due to interruption of the drug supply is prob_supply_interrupted per 3 months 
(base value: 0.01).  The rate of resupply (prob_supply_resumed) has a base value 0.8 per 3 months.  This will vary 
by setting.  There have been reported to be significant issues with drug stock-outs in Zimbabwe in the past 
(http://www.irinnews.org/report/97224/still-struggling-with-drug-shortages).   For patients who have 
interrupted ART due to interruption of supply the probability of restarting ART per 3 months is 
prob_supply_resumed (base value 0.8). 
 
 
Loss to follow-up while off ART (for reasons apart from drug stock-outs) 
 
The probability per 3 months of interrupting/stopping clinic visits (i.e. being lost to follow-up) is rate_lost (base 
vale 0.05) if adherence average adhav > 80%.  This is increased by 1.5 fold if 50% < adhav < 80% and by 2-fold if 
adhav < 50%.  This high rate is informed by the fact that low numbers of people attending clinics after having 
been initiated on ART are not still on ART (e.g. WHO 2012 Resistance report).  Interruption of ART and loss to 
follow-up are assumed correlated with the underlying tendency to adhere when on ART because we assume 
that the same underlying social, practical and economic factors will be an underlying cause of these behaviours.   
 
For people lost to follow-up who are asymptomatic, the probability of returning to clinic per 3 months is 
rate_return (base value 0.05) if adherence average adhav  > 80%.  This is decreased by 2-fold if 50% < adhav < 
80% and by 3-fold if adhav < 50%.  If a person develops a new WHO 3 or 4 event then they are assumed to 
return to the clinic with probability 1.  As mentioned above, this leads to an overall rate of restarting of ART 
after interruption (including having been loss to follow-up in many cases) consistent with the estimates from 
South Africa from Kranzer et al, although these will vary by setting (Charurat 2010;Fox 2012;Kranzer 2010).    
 
As output from the model, the retention on ART at 1 year is 94% amongst those still alive.  This is difficult to 
compare with estimates from the literature because few studies are able to know the outcome status of all 
people initiated on ART, and a high proportion of those lost from a given clinic in fact remain on ART at another 
clinic or have died.  However, taking this into account, this modelled output value of 94% seems consistent with 
data from the WHO Drug Resistance Surveillance Report (2012) (see Figure S17). 
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Figure S17.   Status at 1 year from start of ART.  Data is from WHO Drug Resistance Surveillance Report (2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effect of ART on viral load, CD4 count, resistance development and drug toxicity 
 
This section describes the determination of updated viral load, CD4 count, and acquisition of new resistance 
mutations in a given time period for people on ART.  The updated viral load, CD4 count and risk of new 
resistance mutations appearing all depend on the effective adherence in the previous and current period, the 
number of active drugs (nactive(t-1)) and the current viral load, as well as the time period from the last time ART 
was started or restarted.  The values of viral load, CD4 count, and resistance mutation risk for any combination 
of these factors are given in Table S14 below.  The rationale behind this approach and how the specific values in 
the table were chosen is explained below.  The choice of values is directly informed by studies in this area and by 
comparison of model outputs with data.  For the new resistance mutation risk, the number in the table is 
multiplied by the viral load (mean of values at t-1 and t) to give a value for the variable newmut, which is used 
when assessing whether a new mutation or mutations have arisen (see below).   
 
 
Number of active drugs 
 
We use the concept of the number of drugs that are active, based on presence of resistance mutations to the 
drugs being used.  The level of resistance is determined by the presence of drug resistance mutations, with a 
given set of mutations being translated into a level of resistance to a given drug on a scale of 0 to 1 in the same 
way as is done for common resistance interpretation systems.  The activity level of a drug is then calculated as 1 
minus the level of resistance to the drug. The ability of the number of active drugs, or the genotypic sensitivity 
score, to predict the viral load outcome is well established (DeGruttola 2000), and the concept of using a 
genotypic score to define “optimised background therapy” has been common to the design of several trials in 
treatment experienced patients (e.g. (Grinsztejn 2007)). 
 
Classification of adherence levels 
 
While we model the adherence level for each individual at each three month time period as a value between 0 
and 100%, to determine the viral load, CD4 count and resistance risk, we classify adherence into three levels.   
This is the simplest approach that allows inclusion of the fact that the relationship between adherence and 
resistance risk is not linear, since the risk of resistance tends to be lower when the adherence is either low or 
high, and the risk of resistance is highest when adherence is moderate, allowing enough replication for 
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mutations to be selected for and enough drug present to allow selection of virus with resistance mutations 
(Bangsberg 2004;Gardner 2009;Rosenbloom 2012).    
 
The cut-offs used to define the three adherence levels are 50% and 80%.  Adherence-resistance and adherence-
viral load relationships differ by regimen type and even specific regimen within a class and any overall 
breakdown into groups is necessarily a simplification.  A cut off of 80% is chosen as the upper level as (unlike for 
unboosted PI regimens) at adherence levels of at least 80%, NNRTI and boosted PI regimens are likely to have 
maximal or close to maximal effects on viral load and minimal risk of resistance selection (Parienti 2007).  Actual 
risk of resistance probably depends on the pattern of adherence, not just the average over a three month 
period, so that a treatment interruption of over 1 week during the three month period, while maintaining an 
overall average adherence of 80%, could lead to a higher level of risk of resistance emergence than a situation in 
which the adherence was more uniform over the period (Genberg 2012), although in people who have ongoing 
viral suppression NNRTI regimens seem to be generally robust to even relatively low levels of adherence 
(Cambiano 2010b;Gross 2008;Meresse 2014;Parienti 2007).  A level below 50% is one that that has been 
associated with raised risk of detectable viral load (Arnsten 2001;Genberg 2012)  
 
Determination of viral load, CD4 count and risk of resistance in people on ART 
 
Viral load, CD4 count and risk of resistance in the first 3 months after (re-)starting ART 
 
Table S14a shows how the viral load, CD4 count and risk of resistance is determined for people in the first 3 
months after starting ART or re-starting ART after an interruption of at least 3 months.  Since in this early period 
on ART, the viral load will depend on the initial value the updated viral load is given as a reduction from the pre-
ART maximum viral load.  If the number of active drugs is three or more then at a high adherence level (above 
0.8) the mean viral load change from the pre-ART maximum is 3 log copies/mL.  To reflect the fact that there is 
variability in the response (Montaner 1998), the value for a given person is sampled from a Normal distribution 
with standard deviation 0.2.  This viral load response diminishes both with decreasing number of active drugs in 
the regimen being started (which is informed by data from studies relating GSS to virologic outcome, as well as 
by studies of mono and dual therapy regimens (DeGruttola 2000;Eron 1995;Havlir 1995;Kuritzkes 1996;Larder 
1995;Phillips 1997;Wittkop 2011;Wittkop 2013).  The viral load response also diminishes with decreasing level of 
adherence (see Figure S18 and for example Genberg et al).  As is well established, the CD4 count response 
generally mirrors the viral load response, although with very low numbers of active drugs and low adherence 
there is a mean decrease in CD4 count and still a small decrease in viral load from the maximum.     
 
Figure S18.  Model output: of people on ART, percent with current VL >500 according to current adherence.   
Comparison with data from Genberg at el on electronic monitoring-based adherence measures. 
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Regarding the risk of new drug resistant mutations arising, Tables S14a-S14c provide a number for “new 
mutation risk” that is multiplied by the viral load (mean of values at t-1 and t) to give a probability used when 
assessing whether a new mutation(s) has/have arisen.   Values of the new mutations risk have been chosen in 
conjunction with the translation of presence of mutations into reduced drug activity to provide estimates of 
resistance accumulation consistent with those observed in clinical practice (Gallant 2004;Harrigan 
2005;Johannessen 2009;Ledergerber 1999;Phillips 2001;Phillips 2005;Staszewski 1999a;Staszewski 1999b;van  
Leth 2004).  Risk of new resistance mutations arising increases with decreasing number of active drugs, 
reflecting the known greater risk of resistance with regimens less able to suppress viral replication, most clearly 
seen in the fact that mono and dual therapy regimens are highly susceptible to resistance development (Havlir 
1995;Kuritzkes 1996;Larder 1995).  At low adherence levels, the risk of resistance development is generally low 
regardless of the number of active drugs, as drug selection pressure is low.  However, for those on NNRTI 
regimens the new resistance mutation risk is assumed to be that for the effective adherence category of 50 – 
80% (i.e. maximal) even if the effective adherence is below 50%, reflecting the fact that NNRTI resistance 
develops easily, even when drug exposure is very low (Bangsberg 2004;Bangsberg 2006b).   
 
Viral load, CD4 count and risk of resistance between 3-6 months from (re-)starting ART  
 
For the period 3-6 months from (re-)start of ART (Table S14b; to reduce the table content we do not provide the 
matrices of values for the resistance risk or CD4 count, only for the viral load – available in Cambiano et al 2014) 
we consider the adherence in both the current and previous 3 month period, since the likelihood of reaching 
viral suppression by 6 months will depend on adherence throughout the whole 6 month period from start of 
ART, although the adherence in the current period is assumed to be the stronger factor.  By 6 months after 
starting ART, those on 3 or more active drugs with consistently high adherence generally reach a relatively high 
level of viral suppression, regardless of pre-ART maximal viral load, so a person’s viral load is no longer given by 
the change from baseline but the absolute level of viral load which it is likely they have reached.  In these 
optimal conditions of high adherence and maximal active drugs we assume the viral load has a mean value of 
0.5 log, again with variability between individuals.  Since most viral load assays have a lower limit of 
quantification of 40 or 50 copies per mL, it is not actually known what the actual viral load level is, although 
highly sensitive assays suggest that a proportion of patients reach below 5 copies/mL (0.7 log copies/mL) (Doyle 
2012).  At lower numbers of active drugs and lower adherence, the viral load is still related to the maximal pre-
ART viral load rather than being an absolute value, as the person’s viral load has not become so low that the 
initial value loses relevance.   The viral load response decreases with a lower number of active drugs, lower 
current adherence, and lower adherence in the previous 3 month period.  Values for the viral load response 
between those known from studies (high level of suppression for 3 active drugs and maximal adherence, and 
only around 0.5 log viral suppression when adherence is < 0.5 even with three active drugs (Gross 2001;Wittkop 
2011) are imputed assuming a monotonic relationship. CD4 count responses again mirror the viral load 
response, as has been extensively studied in patients with ongoing viraemia on ART (Ledergerber 2004).  Risk of 
new resistance mutations again increases with decreasing number of active drugs, if current adherence is in the 
middle or highest group.  The only situation in which risk of new mutations is extremely low is when the number 
of active drugs is 3 or close to 3 and the current adherence is in the high category. 
 
Viral load, CD4 count and risk of resistance after 6 months of (re-)starting ART  
 
Table S14c shows how the viral load, CD4 count and risk of resistance is determined for the situation where a 
person has been on ART for more than 6 months and the viral load is suppressed or partially suppressed (< 4 log 
copies/mL).   These values are similar to those used for the period 3-6 months from start of ART except that 
there is assumed to dependence on the adherence in the current 3 month period only. 
 
The situation where the viral load is above 4 log copies /mL, 10,000 copies/mL is treated the same as that in the  
period 3-6 months from start of ART (described above), with adherence in the current and previous period 
having some influence.   
 
Comparisons between model outputs and data from the literature in Figures S10-S14 and S16 help to illustrate 
the extent to which the model captures various aspects of virologic responses to ART.   Tables S15 and S16 
provide estimates from the model on various other outcomes at time points from start of ART.   
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Table S14a.  Viral load (mean change from viral load max), CD4 count change (mean change between t-1 and t), and new mutation risk in first 3 months.  For 0 
active drugs, these are the changes regardless of time from start of ART.  For viral load this is the mean of a Normal distribution with standard deviation 0.2, from 
which the patient's value/change is sampled.  For the CD4 count patients vary in their underlying propensity for CD4 rise on ART (given by sampling from 
lognormal(1,0.52) and the CD4 count change given here is multiplied by this factor.  For the new mutation risk, this is a number that is multiplied by the viral load 
(mean of values at t-1 and t). The resulting probability is used when assessing whether a new mutation or mutations have arisen.   
 
     
   Effective   Number of active drugs 
   adherence  
   between 
   t-1 & t   3 2.75 2.5 2.25 2.0 1.75 1.5 1.25 1 0.75 0.5 0.25 0  
       
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
Viral load  > 80%   -3.0 -2.6 -2.2 -1.8 -1.5 -1.25 -0.9 -0.8 -0.7 -0.55 -0.4 -0.3 -0.3   
(log change > 50%, < 80%  -2.0 -1.6 -1.2 -1.1 -0.9 -0.8 -0.6 -0.5 -0.4 -0.25 -0.1 -0.05 -0.1   
from vmax) < 50%    -0.5 -0.4 -0.3 -0.25 -0.2 -0.15 -0.0 +0.05 +0.1 +0.1 +0.1 +0.1 -0.0   
 
CD4 count  > 80%   +50 +45 +40 +35 +30 +25 +20 +17 +13 +10 +5 -2 -15   
change > 50%, < 80%  +30 +30 +23 +20 +15 +13 +10 +8 +5 +3 +0 -7 -17   
(t-1 to t) < 50%    +5 +4 +3 +2 +1 -1 -3 -6 -10 -11 -12 -13 -18   
 
new mutation  > 80%   0.002 0.01 0.03 0.05 0.1 0.15 0.2 0.3 0.4 0.45 0.5 0.5 0.5   
risk   > 50%, < 80%  0.15 0.15 0.2 0.25 0.3 0.3 0.3 0.35 0.4 0.45 0.5 0.5 0.5   
(x log viral load) < 50%*    0.15 0.15 0.2 0.25 0.3 0.3 0.3 0.35 0.4 0.45 0.5 0.5 0.5 
 < 50%**   0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05   
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
* for NNRTI containing regimen, ** for boosted PI containing regimen.  
      
 51 
Table S14b.  Summary of viral load (mean absolute value or mean change from viral load max) between 3-6 months, and after 6 months if viral load at t-1  > 4 logs.  
This is the mean of a Normal distribution with standard deviation 0.2, from which the patient's value/change is sampled.   
       
Effective adherence Effective adherence   Number of active drugs 
between  between 
t-2 & t-1  t-1 & t    3 2.75 2.5 2.25 2.0 1.75 1.5 1.25 1 0.75 0.5 0.25  
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ 
> 80%   > 80%    0.5 0.8 1.2 1.4 2.0  2.7 -1.7 -1.15 -0.9 -0.75 -0.6 -0.4 
> 50%, < 80%  > 80%    1.2 1.2 1.2 1.4 -2.0 -1.6 -1.2 -1.05 -0.9 -0.7 -0.5 -0.35 
< 50%   > 80%    1.2 1.2 1.2 1.4 -2.0 -1.6 -1.2 -1.0 -0.9 -0.7 -0.5 -0.2 
 
> 80%   > 50%, < 80%   1.2 1.6 1.8 2.2  2.4 -2.4 -1.5 -0.9 -0.7 -0.55 -0.4 -0.3 
> 50%, < 80%  > 50%, < 80%   2.5 2.5 2.5 2.5 -1.2 -1.1 -0.8 -0.65 -0.5 -0.35 -0.2 -0.05 
< 50%   > 50%, < 80%   -2.0 -1.8 -1.5 -1.35 -1.2 -1.1 -0.8 -0.65 -0.5 -0.2 -0.2 -0.05 
 
> 80%   < 50%    -0.5 -0.4 -0.3 -0.25 -0.2 -0.15 -0.10 -0.05 +0.0 +0.0 +0.0 +0.0 
> 50%, < 80%  < 50%    -0.5 -0.4 -0.3 -0.25 -0.2 -0.15 -0.10 -0.05 +0.0 +0.0 +0.0 +0.0 
< 50%   < 50%               -0.5 -0.4 -0.3 -0.25 -0.2 -0.15 -0.10 -0.05 +0.0 +0.0 +0.0 +0.0 
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ 
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Table S14c.  Summary of viral load (mean change from viral load max), CD4 count change (mean change between t-1 and t), and new mutation risk after 6 months, 
where viral load at t-1 < 4 logs.  For viral load this is the mean of a Normal distribution with standard deviation 0.2, from which the patient's value/change is sampled.  
For the CD4 count patients vary in their underlying propensity for CD4 rise on ART (given by sampling from lognormal(1,0.52) and the CD4 count change given here is 
multiplied by this factor.  For the new mutation number, this is a number that is multiplied by the viral load (mean of values at t-1 and t). The resulting probability is 
used when assessing whether a new mutation or mutations have arisen. 
        
   Effective  Number of active drugs 
   adherence 
   between 
   t-1 & t   3 2.75 2.5 2.25 2.0 1.75 1.5 1.25 1 0.75 0.5 0.25  
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
Viral load  > 80%   0.5 0.9 1.2 1.6 -2.5 -2.0 -1.4 -1.15 -0.9 -0.75 -0.6 -0.3 
(absolute value > 50%, < 80%  1.2 1.2 1.2 1.4 -1.2 -1.0 -0.7 -0.6 -0.5 -0.4 -0.3 -0.1 
or log change < 50%    -0.5 -0.4 -0.3 -0.25 -0.2 -0.2 -0.1 -0.1 -0.1 -0.1 -0.1 -0.0 
from vmax) 
 
CD4 count  > 80%   +30 +28 +25 +23 +21 +19 +3 -5 -9 -10.5 -12 -12 
change > 50%, < 80%   +15 +13 +10 +8 -4.5 -7.5 -10 -12 -13 -14 -15 -15 
 (t-1 to t) < 50%    -13 -14 -15 -15.5 -16 -16.5 -17 -17 -18 -17 -17 -17 
    
new mutation  > 80%   0.002 0.01 0.03 0.08 0.10 0.15 0.2 0.3 0.4 0.45 0.5 0.5 
risk   > 50%, < 80%  0.15 0.18 0.2 0.25 0.3 0.3 0.3 0.35 0.4 0.45 0.5 0.5 
(x log viral load)  < 50%*    0.15 0.18 0.2 0.25 0.3 0.3 0.3 0.35 0.4 0.45 0.5 0.5 
 < 50% **  0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 
 
  
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
* for NNRTI containing regimen, ** for boosted PI containing regimen.
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Table S15.   Model outputs of Status of people who started ART, according to time since initiation.   
 
        Number of years since start ART 
Status         1 3 5 10 
  
-------------------------------------------------------------------------------------------------------------------------------------- 
On ART VL < 500      76% 65% 56% 39% 
         
On ART VL > 500 no resistance      3% 3% 2% 1% 
         
On ART VL > 500 with 1 or more resistance mutation  7% 8% 6% 5% 
         
Off ART but under care      3% 3% 3% 2% 
        
Off ART not under care      2% 4% 4% 4% 
        
Dead AIDS       5% 10% 16% 27% 
         
Dead non-AIDS       3% 8% 12% 21% 
-------------------------------------------------------------------------------------------------------------------------------------- 
 
 
Table S16.  Model-derived Kaplan-Meier estimates of proportion experiencing various outcomes by 
years from initiation of ART.   
 
    Years from start of ART  
    1   3   5   10  
   
---------------------------------------------------------------------------------------------------------------------------------- 
Viral load failure*  9  17  25  38 
 
Resistance mutation  8  14  18  25 
(with virologic failure)   
 
CD4 count rise of > 100/mm3 59  84  90  95   
 
CD4 count rise of > 200/mm3 17  63  77  88   
    
Interruption   14  31  44  68 
     
Loss to follow-up  4  10  15  28 
     
Death    8  17  25  44 
------------------------------------------------------------------------------------------------------------------------------------ 
* considering viral load annually only, for consistency with countries where virologic failure monitore 
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Variable patient-specific tendency for CD4 count rise on ART 
 
There is variability in the tendency for the CD4 count to rise on ART, for a given level of viral load 
suppression.  For scenarios in the above table (S14) in which the CD4 count change is positive the 
CD4 count change is modified by this patient-specific factor (i.e. it is fixed for each patient), which is 
given by sampling for each patient from 
 
Exp ( N(0, (sd_patient_cd4_rise_art)2)   
 
sd_patient_cd4_rise_art =  0.2  
 
To reflect the fact that the rate of CD4 count increase on ART tends to diminish with time, for those 
with patient-specific factor determining the CD4 count rise on ART > 1, this factor is modified by a 
factor 0.25 after 2 years of continuous treatment.   
 
Accelerated rate of CD4 count loss if PI not present in regimen 
 
The rate of change in CD4 count in people on failing regimens is largely based on data from the 
PLATO collaboration, for which patients were mainly on regimens containing a PI.  If the regimen 
does not contain a PI the change in CD4 count per 3 months is modified (in the base model) by 
poorer_cd4_rise_on_failing_nnrti (= -6 /mm3).  This applies regardless of viral load level, so PIs are 
assumed to lead to a more beneficial CD4 count change than NNRTIs (Ledergerber 2004).   
 
Variability in individual (underlying) CD4 counts for people on ART 
 
Once the mean of the underlying CD4 count is obtained as described above for people on ART, to 
obtain the CD4 count, variability (sd_cd4  = 1.2) is added on the square root scale.  The estimate was 
based on unpublished analyses. 
 
Viral load and CD4 count changes during ART interruption 
Viral load returns to previous maximum viral load (vmax) in 3 months and adopts natural history 
changes thereafter.   
 
CD4 rate of decline returns to natural history changes (ie those in ART naïve patients) after 9 
months, unless the count remains > 200 above the CD4 nadir   
 
Rate of CD4 count decline depends on current viral load. c(t) is the CD4 count at time t, cmin(t) is the 
CD4 count nadir measured by time t and cc(t-1) is the change in CD4 count from t-1 to t. v 
 
if time off ART = 3 or if time off ART > 3 months and CD4 in previous period is > 300 above the 
minimum CD4 count to date  
  v(t) = vmax(t-1)  
 if v(t) > 5   then cc(t-1)  =  Normal (-200,102)   
 if 4.5 <= v(t) < 5  then cc(t-1)  =   Normal (-160,102) 
if v(t) < 4.5   then cc(t-1)  =   Normal (-120,102) 
 
If this leads to c(t) < cmin(t) (CD4 nadir) then c(t) is set to cmin(t) 
if time off ART = 6 months:-   
if v(t) > 5   then cc(t-1)  =  Normal (-100,102)   
 if 4.5 <= v(t) < 5  then cc(t-1)  =   Normal (-90,102) 
if v(t) < 4.5   then cc(t-1)  =   Normal (-80,102) 
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if time off ART = 9 months:-  
      if v(t) > 5   then cc(t-1)  =  Normal (-80,102)   
 if 4.5 <= v(t) < 5  then cc(t-1)  =   Normal (-70,102) 
if v(t) < 4.5   then cc(t-1)  =   Normal (-60,102) 
 
This is broadly based on evidence from a number of analyses of the effects of ART interruption (e.g. 
d'Arminio Monforte 2005, Li X 2005, Mocroft 2001, Wit 2005) 
 
Incidence of new current toxicity and continuation of existing toxicity 
Toxicities including gastrointestinal symptoms, rash, hepatoxicity, CNS toxicity, lipodystrophy, 
hypersensitvity reaction, peripheral neuropathy and nephrolithiasis can occur with certain 
probability on certain specific drugs.  These probabilities are based broadly on evidence from trials 
and cohort studies, although there are no common definitions for some conditions which 
complicates this.  
 
Table S17.  Risk of development of specific drug toxicities. 
Toxicity Drug Risk of development per 3 months Probability of 
continuation if pre-
existing 
Nausea atazanavir 1% (5-fold higher in 1st year) 50% 
Zidovudine, ddI, 
lopinavir 
3% (5-fold higher in 1st year) 50% 
ddI 5% (2.5-fold higher in 1st year) 50% 
lopinavir 2% (2.5-fold higher in 1st year) 50% 
atazanavir 1% (2.5-fold higher in 1st year) 50% 
Rash efavirenz 3% (in first 6 months on efavirenz)  
nevirapine 10% (in first 6 months on nevirapine)  
CNS toxicity efavirenz 10% (if been on efavirenz <1 year) 80% if been on 
efavirenz <1 year. 90% 
if been on efavirenz ≥1 
year 
Lipodystrophy d4T 5% 100% 
 Zidovudine 1.5% 100% 
Peripheral 
neuropathy 
d4T 2% (1.5-fold higher in 1st year) 100% (if remain on d4T) 
ddI 1% (1.5-fold higher in 1st year) 100% (if remain on ddI) 
Acute hepatitis nevirapine 2% (one off risk in 1st and 2nd 3 month 
periods) 
 
Anaemia zidovudine 3% (1.5-fold higher in 1st year) 20%  
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Headache ZDV 10% (1.5-fold higher in 1st year) 40% 
Pancreatitis D4T, DDI 0.5% (1.5-fold higher in 1st year) 100% 
Lactic acidosis d4T, ddI 1%  
Zidovudine, 
tenofovir 
0.01%  
Renal 
dysfunction 
tenofovir 0.35%  
 
 
 
Switching of drugs due to toxicity 
 
If toxicity is present then individual drugs may be switched due to toxicity (nevirapine for efavirenz, 
zidovdine for tenofovir).  ddI is only used if neither zidovudine and tenofovir are available due to 
toxicity. 
 
 
 
7.  Emergence of specific resistance mutations and their effect on drug activity 
 
 
Accumulation of resistance mutations 
newmut (see Table S14 above) is a probability used to indicate the level of risk of new mutations 
arising in a given 3 month period.  If this chance comes up in a given 3 month period (determined by 
sampling from the binomial distribution) then the following criteria operate. 
 
 
Table S18.  Risk of acquiring new resistance mutations. 
 
Resistance mutation 
Probability 
of arising Conditions 
M184 50% if (on 3TC)  
# TAMS increases by 1 20% if (on ZDV or d4T) and (not on 3TC nor FTC) 
 12% if (on ZDV or d4T) and (on 3TC or FTC) 
# TAMS increases by 2 1% if (on ZDV or d4T) and (not on 3TC nor FTC) 
 1% if (on ZDV or d4T) and (on 3TC or FTC) 
K65 2% if (on tenofovir or ddI) and (on zidovudine or d4T)  
 10% If (on tenofovir or ddI) and (not on zidovudine nor d4T)  
L74 1% if (on ddI)  
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Q151 2% if (on ddI or d4T or zidovudine)  
K103 20% If on nevirapine 
 60% If on efavirenz 
Y181 40% If on nevirapine 
 10% If on efavirenz 
G190 20% If on nevirapine 
 10% If on efavirenz 
V32 4% if on lopinavir 
I47 4% If on lopinavir 
I50L 3% If on atazanavir 
L76 4% If on lopinavir 
   
I84 3% If on atazanavir 
N88 3% If on atazanavir 
 
These values are chosen, in conjunction with values of newmut{t}, to provide estimates of 
accumulation of specific classes of mutation consistent with those observed in clinical practice  (UK 
Drug Resistance Database 2005, Harrigan 2005, Sigaloff 2012).  They reflect a greater propensity for 
some mutations to arise than others. This probably relates to the ability of the virus to replicate 
without the mutations (e.g. probably very low in the presence of 3TC for virus without M184V) as 
well as the replicative capacity of virus with the mutations.  Over time as more data accumulate it 
may be possible improve these estimates of rates of accumulation of specific mutations. 
 
New resistance to NNRTI arising as a result of ART interruption 
 
It is assumed that due to the long half life of NNRTIs nevirapine and efavirenz, stopping of a regimen 
containing one of these drugs is associated with a probability (= 0.05)  of an NNRTI resistance 
mutation arising (see, for example, Fox et al, 2008).   
 
 
Loss of acquired mutations from majority virus 
 
It is assumed that mutations tend to be lost from majority virus with a certain probability from 3 
months after stopping to take a drug that selects for that mutation.  The probability of losing 
mutations per 3 months (from 3 months after stopping) is as follows (Devereux  1999,  Devereux 
2001, Deeks  2003, Birk 2001, Walter 2002, Hance 2001, Tarwater PM  2003) 
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Table S19.   Probability of loss of acquired mutations from majority virus per 3 months after stopping 
drugs selecting for mutation. 
---------------------------------------- 
M184V   0.8  
L74V   0.6 
Q151M   0.6 
K65R   0.6 
TAMS (lose all)  0.4 
NNRTI mutations 0.2 
Protease  mutations 0.2 
--------------------------------------- 
 
Mutations are regained in majority virus if a drug selecting for the mutation is again started. 
 
 
Determination of level of resistance to each drug 
 
Table S20 shows the level of resistance to each drug according to presence of specific resistance 
mutations. 
 
Table S20.  Level of resistance to each drug according to presence of specific resistance mutations. 
 
Resistance mutation Drug 
Level of resistance  
(1=full resistance) 
Condition 
M184 3TC or FTC 0.75  
1-2 TAMS zidovudine or 
d4T  0.5 
No 3TC or FTC in regimen 
 zidovudine or 
d4T  0.25 
3TC or FTC in regimen and ever had 
M184V 
 zidovudine or 
d4T 0.5 
3TC or FTC in regimen and never 
had M184V  
2-3 TAMS tenofovir 0.5 No 3TC or FTC in regimen 
 tenofovir 
0.25 
3TC or FTC in regimen and ever had 
M184V 
 tenofovir 
0.5 
3TC or FTC in regimen and never 
had M184V  
3-4 TAMS zidovudine or 
d4T  0.75 
No 3TC or FTC in regimen 
 zidovudine or 
d4T 0.5 
3TC or FTC in regimen and ever had 
M184V 
 zidovudine or 
d4T  0.75 
3TC or FTC in regimen and never 
had M184V  
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3 or more TAMS ddI 0.5  
4 or more TAMS tenofovir 0.75 No 3TC or FTC in regimen 
 tenofovir 
0.5 
3TC or FTC in regimen and ever had 
M184V 
 tenofovir 
0.75 
3TC or FTC in regimen and never 
had M184V  
5 or more TAMS zidovudine or 
d4T 1.0 
No 3TC or FTC in regimen 
 zidovudine or 
d4T  0.75 
3TC or FTC in regimen and ever had 
M184V 
 zidovudine or 
d4T 0.75 
3TC or FTC in regimen and never 
had M184V  
Q151 zidovudine or 
d4T ddI 0.75 
 
K65 d4T 0.5  
 tenofovir or 
ddI 0.75 
 
 ddI 0.75  
K103 nevirapine or 
efavirenz 1.0 
 
Y181 nevirapine 1.0  
 efavirenz 0.75  
G190 nevirapine 1.0  
 efavirenz 0.75  
I47 lopinavir 0.75  
I50L atazanavir 1.0  
 atazanavir 1.0  
N88 atazanavir 1.0  
1 of (G48, I84) atazanavir 0.5  
1 of (G48, I84) atazanavir 1.0 
Ever had at least 2 of (V32, M46, 
I54, V82, L90) 
Both of (G48, I84) atazanavir 1.0  
1 or 2 or 3 of (V32, M46, I54, 
V82, L90) atazanavir 0.5 
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At least 4 of (V32, M46, I54, 
V82, L90) atazanavir 1.0 
 
1 of (V32, L76, V82) lopinavir 0.25 Never had I47 
2 of (V32, L76, V82) lopinavir 0.5 Never had I47 
3 of (V32, L76, V82) lopinavir 0.75 Never had I47 
All of (V32, I47, L76, V82) lopinavir 1.0  
4 of (M46, V82, I84, L90) Lopinavir 
Max(level of 
resistance as above in 
this table, 0.5) 
 
2 or 3 of (M46, V82, I84, L90) lopinavir 
Max(level of 
resistance as above in 
this table, 0.25) 
 
 
These rules approximately follow the interpretation systems for conversion of mutations present on 
genotypic resistance test into a predicted level of drug activity (or, equivalently, of resistance; 
http://www.rega.kuleuven.be, http://hivdb.stanford.edu, http://www.hivfrenchresistance.org/ 
 
 
 
Calculation of activity level of each drug 
 
This is given by 1-level of resistance.  For ritonavir boosted PIs it is given by 2 – (2 x level of 
resistance);  i.e. assumed higher potency due to ability to induce sustained viral suppression alone.  
Activity levels of each drug in the regimen are summed to give the total number of active drugs. 
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8.  Risk of clinical disease and death in HIV infected people 
 
 
Occurrence of WHO 4 diseases  
The rate of WHO 4 diseases according to CD4 count per 3 months is given below. 
 
 
Table S20.  Rate of WHO stage 4 disease according to CD4 count and viral load. 
 
--------------------------------------------------------------------------------------------------------------------------------- 
If cd4 > 650   rate=0.002 
if 500 < cd4 < 650        rate=0.010      if 450 < cd4 < 500      rate=0.013      
if 400 < cd4 < 450        rate=0.016       if 375 < cd4 < 400       rate=0.020      
if 350 < cd4 < 375        rate=0.022       if 325 < cd4 < 350       rate=0.025     
if 300 < cd4 < 325        rate=0.030      if 275 < cd4 < 300       rate=0.037     
if 250 < cd4 < 275        rate=0.045      if 225 < cd4 < 250       rate=0.055     
if 200 < cd4 < 225        rate=0.065      if 175 < cd4 < 200       rate=0.080     
if 150 < cd4 < 175        rate=0.10      if 125 < cd4 < 150       rate=0.13      
if 100 < cd4 < 125        rate=0.17       if 90 < cd4 < 100       rate=0.20     
if 80 < cd4 < 90        rate=0.23       if 70 < cd4 < 80       rate=0.28      
if 60 < cd4 < 70        rate=0.32      if 50 < cd4 < 60       rate=0.40      
if 40 < cd4 < 50        rate=0.50       if 30 < cd4 < 40       rate=0.80      
if 20 < cd4 < 30        rate=1.10       if 10 < cd4 < 20       rate=1.80      
if 0 <  cd4 < 10        rate=2.50      
 
Independent effect of viral load 
 
if v < 3     rate = rate x 0.2 
if 3 <= v < 4    rate = rate x 0.3 
if 4 <= v < 4.5    rate = rate x 0.6 
if 4.5 <= v < 5    rate = rate x 0.9 
if 5 <= v < 5.5    rate = rate x 1.2 
if 5.5 <= v   rate = rate x 1.6 
--------------------------------------------------------------------------------------------------------------------------------- 
 
This is informed by Phillips AIDS 2004. 
 
Independent effect of age 
 
rate = rate x (age / 38)1.2 
 
Independent effect of PJP prophylaxis 
 
If patient on PJP prophylaxis then this rate is multiplied by 0.8. 
 
If CD4 count is meausured and current value < 350 /mm3 then patient assumed to have 80% chance 
of starting PJP prophylaxis after 1996 
 
If patient has current WHO stage 3 or 4 condition they are assumed to have an 80% chance of 
starting PJP prophylaxis 
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If CD4 count is measured then PJP prophylaxis assumed to stop if current value > 350/mm3. 
 
If the patient has been continuously on ART for 2 years with no WHO 3 or 4 condition in previous 6 
months then it is assumed that PJP prophylaxis is stopped. 
 
 
Independent effect of being on ART 
 
For patients on a single drug regimen this risk is multiplied by 0.9, for patients on a two drug 
regimen it is multiplied by 0.85 and for patients on a 3 drug regimen it is multiplied by 0.6, to reflect 
that being on ART has a positive effect on risk of AIDS and death independent of latest CD4 count 
and viral load. 
 
 
Occurrence of WHO 3 diseases  
As for WHO 4 except risk is fold_incr_who3 (= 5) higher. 
 
 
Risk of HIV-related death  
 
As for WHO 4 except risk fold_decr_hivdeath - fold lower (= 0.25).   
 
CD4-, viral load- age-specific death rate raised incr_death_rate_tb-fold (= 10) if current TB and 
incr_death_rate_adc-fold (= 10) if current WHO 4 disease.  We assume 15% of HIV-related deaths (ie 
not including deaths that arise due to background mortality rates) are classified as non-HIV-related.   
 
 
 
9.   Details relating to modelling the monitoring strategies 
 
A key consideration in modelling use of viral load measured using dried blood spots (DBS) from 
whole blood is to take account the reduced accuracy of detection of viral load > 1000 copies/mL, 
compared to measurement on a plasma sample obtained by phlebotomy, which relates to low 
sample volume and presence of ribonucleic acid (RNA) in cells which may be inadvertently amplified 
along with RNA in plasma.  As part of modelling the underlying natural history of HIV and the effect 
of ART we model the true underlying viral load, and then consider the viral load as measured in a 
plasma sample by sampling it from a Normal distribution with mean the true underlying viral load 
and a standard deviation of 0.22 log copies/mL (Brambilla et al 1999, Raboud et al 1996).  Viral load 
as measured in DBS has been compared with viral load measured in plasma with varying results, but 
the standard deviation of the difference between the measurement in plasma and on DBS  has been 
found to be in the region of 0.4-0.6 log copies/mL, with greater variability at lower viral load levels 
(Andreotti et al 2010, Marconi et al 2009, Arredondo et al 2011, Pirillo MF-Pinson et al 2011, Fajardo 
et al 2014, Smit et al 2014, Ondoa 2014, Mavedzenge 2015), with sensitivity for the 1000 cut-off 
generally varying between 81-95% and specificity generally varying between 88% and 97% (World 
Health Organisation Technical Report), with variation by assay, so selection of assay for DBS is 
important.   
It is unclear whether the variation in viral load results from use of DBS samples compared with 
plasma samples is all additional variability on top of the variation seen in plasma measurement 
compared with actual known virus input (which we have taken as a standard deviation of 0.22).   In 
our base analysis this is determined as follows:  
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Viral load measured on whole blood = 0.5 x true viral load   +  0.5 x viral load measured on plasma  +  
offset + Normal (0, (0.50 +  0.05 x (4 – true viral load))2)  where offset = 0 in the base case.   
This corresponds to an average standard deviation of the difference between VL on whole blood 
(e.g. DBS, or POC which uses whole blood) and plasma of 0.64 log copies/mL.  The sensitivity and 
specificity of detection of a viral load level > 1000 copies/mL varies according to the distribution of  
underlying viral load of those tested, as the variability is higher at low VL level. On average over the 
20 year period this corresponds to sensitivity and specificity of 86% and 92% of DBS (vs plasma), 
respectively, for the 1000 threshold. In sensitivity analyses we consider modifications as follows; (a) 
offset = + 0.5, resulting in sensitivity 96% and specificity 79%, (b) offset = -0.5 (resulting in sensitivity 
71% and specificity 97%, (c) (0.50 +  0.05 x (4 – true viral load))2 replaced by (0.40 +  0.05 x (4 – true 
viral load))2, resulting in sensitivity 88% and specificity 93%, (d)  (0.50 +  0.05 x (4 – true viral load))2 
replaced by ) (0.50 +  0.20 x (4 – true viral load))2, resulting in sensitivity 85% and specificity 79%. 
As well as eliminating the time delay involved with sending samples to a central lab for testing, use 
of POC assays may also reduce loss of samples and results which occurs with transporting to labs and 
communicating results (Rutstein et al 2015), although this must be balanced against the possibility of 
POC instruments occasionally being in need of repair, which occurs also with CD4 count POC 
machines.  In our base case scenario we assume that there is a 0.85 chance of a given viral load or 
CD4 count being done as scheduled with a result successfully received.  In some cases the cost of the 
test will be incurred even when the test result is not received and in the absence of data to inform 
this probability we assume that this occurs with probability 0.25 across all viral load and CD4 tests.   
For our main comparison of the seven monitoring strategies in Table 1 of the main paper, several 
sensitivity analyses were performed in addition to the changes in sensitivity and specificity (a)-(d) 
above.  These are to consider (e) a population adherence profile so there is a greater likelihood of 
poorer adherence,  (f) future increases in condomless sexual behaviour in the population, (g) a 
permanent increase in adherence as a result of viral load measurement alert in none rather than 
40%,  (h) a permanent increase in adherence as a result of viral load measurement alert in 100% 
rather than 40%,  (i) a policy of initiation ofART at diagnosis, (j) a reduced frequency of clinic visits if 
the CD4 count has been measured to be > 350 /mm3 in the past year, (k) a switch rate of 0 (so the 
only benefit of monitoring is to inform who should be seen less frequently), (l) a lower prevalence of 
HIV in 2014 (1.5% instead of 15% in base case),  (m) a higher prevalence of HIV in 2015 (33% instead 
of 15% in base case), (n) a lower proportion on ART in 2015 (33% instead of 56% in base case), (o) a 
higher proportion of people with HIV on ART in 2015 (70% instead of 56% in base case), (p) a 5% 
discount rate instead of 3%,  (q) a 10 year time horizon instead of 20 years, (r) 2 times higher rate of 
ART interruption if visit frequency has been reduced due to viral load being < 1000 copies/mL, and 
(s) 2 times lower rate of ART interruption if visit frequency has been reduced due to viral load being 
< 1000 copies/mL. 
We also carried out the following one way sensitivity analyses around our comparison between viral 
load using DBS and using plasma-based POC test, considering possible further advantages of POC 
tests in addition to the greater accuracy and lack of time delay considered in our main analysis.  We 
considered what this ICER would be if (i) a POC test would have a greater penetration and allow 
reach to a greater proportion of the population (i.e. that 20% of the population would not have 
access to viral load testing unless a POC test was available), (ii) the rate of loss from care for people 
on ART is 20% lower due to POC viral load tests being available, (iii) a POC viral load allows an 
increase in the probability of switch once failure occurs from 0.5 per 3 months to 0.8 per 3 months, 
and (iv) that the error in DBS is all additional error to the plasma level (i.e. rather than being based 
on 0.5 x true viral load   +  0.5 x viral load measured on plasma, being based only on 1.0 x viral load 
measured on plasma).     
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To control Monte Carlo error, 500 repeat runs were done for each strategy and means taken.  To 
assess the stochastic error that remains as a result of this procedure, we repeated the calculation of 
the ICER for viral load-informed differentiated care ($326) 20 times (i.e. 500 runs for no monitoring 
and 500 runs for viral load-informed differentiated care repeated 20 times).  The standard deviation 
for the variability was $5.     
 
10.  Economic Analysis Methods  
To determine cost-effectiveness, the monitoring alternatives ealuated in the study are first ranked 
on the basis of their effectiveness (i.e. from those leading to fewest DALYs incurred in the population 
to the highest DALYs incurred).  Any strategies that are less effective and more costly than one (or a 
linear combination) of other alternatives are then removed.  All remaining strategies are compared 
on the basis of the cost-per-DALY-averted (also known as the incremental cost-effectiveness ratio – 
ICER) compared to the next less effective, less costly alternative.  This can be compared to the costs-
per-DALY-averted (ICERs) associated with other claims on healthcare resources to determine which 
of the alternative monitoring policies represent value-for-money. 
Policymakers should choose the monitoring policy that is expected to lead to greatest health gains 
(i.e. is most effective) as long as the ICER is less than ICERs associated with other HIV and healthcare 
interventions that can no longer be delivered as a result of resources being committed to the 
monitoring approach.  This requires comparison to a cost-effectiveness threshold (CET); which 
represents the ICER(s) of such forgone interventions.  In this way, the monitoring policy would be 
expected to not just improve the health of patients in receipt of monitoring but also maximise health 
across the whole population; and can justifiably be deemed “cost-effective”. 
𝐼𝐶𝐸𝑅 =
𝐼𝑛𝑐𝑟𝑒𝑚𝑒𝑛𝑡𝑎𝑙 𝑐𝑜𝑠𝑡
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝐷𝐴𝐿𝑌𝑠 𝑎𝑣𝑒𝑟𝑡𝑒𝑑
≤ 𝐶𝐸𝑇 
The set of strategies which could feasibly be cost-effective depending on the choice of CET can be 
shown on the cost-effectiveness plane.  In Supplementary Figure 1, those strategies which are cost-
effective at different thresholds are shown linked by a solid line. This set of strategies is referred to 
as the cost-effectiveness frontier. As we move along the line past each strategy, the ICER rises and 
this would only be cost-effective at a higher CET than the previous strategy (as the incremental cost 
per DALY averted is higher than that associated with the previous strategy compared to its less 
effective, less costly comparator).  
As an alternative, but equivalent to the ICER vs. CET decision rule we construct a measure termed 
the net monetary burden of DALYs (NMBn(DALYs)). This is analagous to the measure of net 
monetary benefit that is frequently used in applied cost-effectiveness analysis using quality-adjusted 
life years (QALYs) (Stinnett et al 1998; Drummond et al 2005).  It presents the results on a monetary 
scale, where a treatment is worse given higher costs and greater DALYs, which are converted on to 
the monetary scale using the CET:  
𝑁𝑀𝐵𝑛(𝐷𝐴𝐿𝑌𝑠) = 𝐶𝑜𝑠𝑡𝑠 + (𝐷𝐴𝐿𝑌𝑠 ∗ 𝐶𝐸𝑇) 
To be meaningful to inform investment decisions, the NMBn(DALYs) associated with an intervention 
needs to be compared to other alternatives.  When there is only one comparator, results can be 
expressed incrementally and if the intervention has a negative Inc NMBn(DALYs) it would be deemed 
cost-effective: 
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𝐼𝑛𝑐 𝑁𝑀𝐵𝑛(𝐷𝐴𝐿𝑌𝑠) = 𝐼𝑛𝑐 𝐶𝑜𝑠𝑡𝑠 + (𝐼𝑛𝑐 𝐷𝐴𝐿𝑌𝑠 ∗ 𝐶𝐸𝑇) 
Where there are more than two alternatives, these can be compared on the basis of their 
NMBn(DALYs) with that alternative associated with the lowest value being deemed cost-effective.   
Results are shown using these measures in Table 3 of the main paper.   
When  the inc. NMBn represents the comparison between two different extents to which an 
intervention is implemented, it can be viewed as the maximum amount the healthcare system 
should be willing to spend on implementing the intervention (in addition to the costs of the 
intervention itself)  with it still being regarded as cost-effective.  This can be used to guide the level 
of extra resources that should be committed to improve the implementation and uptake of that 
intervention if it is currently under-provided and/or under-utilized.   
The appropriate CET for any given decision however depends upon the availability of resources in a 
healthcare system and other calls on the available budget.  Robust empirical estimates of CETs for 
low- and middle-income countries are lacking so this is highly uncertain.  In this study, we choose to 
compare ICERs to a range of cost-effectiveness thresholds.  However, as a basis of recommendations 
and when exploring the sensitivity of some assumptions, we choose to use a CET of $500.  We 
believe this is a reasonable estimate for low resource countries in southern Africa, based on research 
and current knowledge that reflects other calls on HIV programme resources (Woods et al 2015).  In 
some cases an appropriate threshold is likely to be higher than this; in other cases a lower threshold 
would be appropriate.   
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11.  Unit Costs and disability weights for DALYs    
 
Table S21.  Unit Costs  
Item Unit Cost Source / explanation 
Drug costs per year  (including 
supply chain): 
  
First-line: 
tenofovir/3TC/efavirenz  
Second-line: 
zidovudine/3TC/atazanavir 
 
 
 
$144 
 
$312 
Untangling the web of antiretroviral price reductions.  17th Edition – July 
2014.  www.msfaccess.org.   
 
Cost of treatment of a WHO 
stage 4 condition over 3 
months (cost is incurred for 3 
months)  
 
Cost of treatment of a WHO 
stage 3 condition over 3 
months (cost is incurred for 3 
months)  
 
Cost of treatment of TB per 3 
months (cost is incurred for 6 
months) 
 
Cotrimoxazole annual cost 
 
$200     
 
 
 
$20         
 
 
 
 
$50        
 
 
 
$5         
Specific data not available on average unit costs of treating WHO stage 3 
and 4 conditions and per clinic visit costs - costs used are informed by 
evidence synthesis from studies that cost according to current CD4 count 
of those in pre-ART care, cost of ART initiation, which also include costs 
of CD4 tests (Eaton J et al.)    
CD4 count measurement      
 
$10 Hyle, E. P., Jani, I. V, Lehe, J., Su, A. E., Wood, R., Quevedo, J., … 
Walensky, R. P. (2014). The Clinical and Economic Impact of Point-of-Care 
CD4 Testing in Mozambique and Other Resource-Limited Settings: A 
Cost-Effectiveness Analysis. PLoS Med, 11(9), e1001725. 
doi:10.1371/journal.pmed.1001725.  Keebler D, Revill P, et al.  How 
Should HIV Programmes Monitor Adults on ART? A Combined Analysis of 
Three Mathematical Models.  Lancet Global Health 2014.  E35-E43. 
Viral load measurement:  
 
$22 Human resource costs $3, sample collection consumables $2, relaying of 
results $2 (this costing information was provided by Medecin Sans 
Frontiers (MSF) (K Bonner), with the most recent information update 
February 2014), running the test (including equipment and other costs 
such as consumables, maintenance and shipping) $15   
(http://www.theglobalfund.org/en/mediacenter/newsreleases/2015-06-
10_New_Approach_on_HIV_Viral_Load_Testing/ 
http://www.theglobalfund.org/en/procurement/viral-load-early-infant-
diagnostics/) 
Non-ART programme costs  
per year, $40 per year if on 
tiered care due to viral load < 
1000      
 
$80 Bill and Melinda Gates Foundation tiered care meeting report (the per 
client cost of running the Khayelitsha adherence clubs was $58 per client 
per year compared to standard clinic care of $108 per client per year. At 
the Infectious Disease Institute in Kampala, the annual costs per client 
for physician, nurse, and pharmacy only visits were $60, $45, and $19, 
respectively). 
Cost of the targeted 
adherence counselling 
intervention triggered by a 
viral load > 1000 copies/mL  
$10    Assumption 
HIV test (including personnel 
costs) 
$10  Eaton J et al.  Health benefits, costs, and cost-effectiveness of earlier 
eligibility for adult antiretroviral therapy and expanded treatment 
coverage: a combined analysis of 12 mathematical models.  Lancet 
Global Health 2014: E23-E34 
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Disability weights  
(informed from Salomon et al*)   
Values are 1 except for the following: 
Condition in current 3 month period Disability weight for current 3 month period 
Any drug toxicity in current 3-month period 0.95 
Any WHO stage 3 condition (except TB) in current 3-
month period 
0.78 
TB in current 3-month period 0.60 
Any WHO stage 4 condition in current 3-month period 0.46 
 
* Salomon JA, Vos T, Hogan DR, et al. Common values in assessing health outcomes from disease 
and injury: disability weights measurement study for the Global Burden of Disease Study 2010. 
Lancet 2012; 380: 2129–43.   
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